Literature DB >> 22122446

The role of Toll-like receptors and adaptive immunity in the development of protective or pathological immune response triggered by the Trypanosoma cruzi protozoan.

Andrea Pellegrini1, Natalia Guiñazu, Laura Giordanengo, Roxana Carolina Cano, Susana Gea.   

Abstract

Trypanosoma cruzi, the causal agent of Chagas disease, is an intracellular protozoan parasite that predominantly invades macrophages and cardiomyocytes, leading to persistent infection. Several members of the Toll-like receptor family are crucial for innate immunity to infection and are involved in maintaining tissue homeostasis. This review focuses on recent experimental findings of the innate and adaptive immune response in controlling the parasite and/or in generating heart and liver tissue injury. We also describe the importance of the host's genetic background in the outcome of the disease and emphasize the importance of studying the response to specific parasite antigens. Understanding the dual participation of the immune response may contribute to the design of new therapies for Chagas disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22122446     DOI: 10.2217/fmb.11.122

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  8 in total

1.  Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.

Authors:  I Bontempi; K Leal; E Prochetto; G Díaz; G Cabrera; A Bortolotti; H R Morbidoni; S Borsuk; O Dellagostin; I Marcipar
Journal:  Clin Exp Immunol       Date:  2020-07-06       Impact factor: 4.330

2.  A missense polymorphism (rs11466653, Met326Thr) of toll-like receptor 10 (TLR10) is associated with tumor size of papillary thyroid carcinoma in the Korean population.

Authors:  Su Kang Kim; Hae Jeong Park; Il Ki Hong; Joo-Ho Chung; Young Gyu Eun
Journal:  Endocrine       Date:  2012-11-03       Impact factor: 3.633

3.  Immunomodulation by Trypanosoma cruzi: toward understanding the association of dendritic cells with infecting TcI and TcII populations.

Authors:  Thiago Alvares da Costa; Marcos Vinicius Silva; Maria Tays Mendes; Tamires Marielem Carvalho-Costa; Lara Rocha Batista; Eliane Lages-Silva; Virmondes Rodrigues; Carlo Jose Oliveira; Luis Eduardo Ramirez
Journal:  J Immunol Res       Date:  2014-10-13       Impact factor: 4.818

4.  Trypanosoma cruzi infection is a potent risk factor for non-alcoholic steatohepatitis enhancing local and systemic inflammation associated with strong oxidative stress and metabolic disorders.

Authors:  Luisina I Onofrio; Alfredo R Arocena; Augusto F Paroli; María E Cabalén; Marta C Andrada; Roxana C Cano; Susana Gea
Journal:  PLoS Negl Trop Dis       Date:  2015-02-10

5.  Toll-like receptor 10-1-6 gene cluster polymorphisms are not associated with benign prostatic hyperplasia in korean population.

Authors:  Su Kang Kim; Young Ock Kim; Byung-Cheol Lee; Koo Han Yoo; Joo-Ho Chung
Journal:  Int Neurourol J       Date:  2014-03-31       Impact factor: 2.835

6.  Apoptotic CD8 T-lymphocytes disable macrophage-mediated immunity to Trypanosoma cruzi infection.

Authors:  M P Cabral-Piccin; L V C Guillermo; N S Vellozo; A A Filardy; S T Pereira-Marques; T S Rigoni; W F Pereira-Manfro; G A DosReis; M F Lopes
Journal:  Cell Death Dis       Date:  2016-05-19       Impact factor: 8.469

7.  Toll-like receptor agonists Porphyromonas gingivalis LPS and CpG differentially regulate IL-10 competency and frequencies of mouse B10 cells.

Authors:  Zhiqiang Liu; Yang Hu; Pei Yu; Mei Lin; Grace Huang; Toshihisa Kawai; Martin Taubman; Zuomin Wang; Han Xiaozhe
Journal:  J Appl Oral Sci       Date:  2017 Jan-Feb       Impact factor: 2.698

8.  NLRP3 Inflammasome and Caspase-1/11 Pathway Orchestrate Different Outcomes in the Host Protection Against Trypanosoma cruzi Acute Infection.

Authors:  Augusto F Paroli; Patricia V Gonzalez; Cintia Díaz-Luján; Luisina I Onofrio; Alfredo Arocena; Roxana C Cano; Eugenio A Carrera-Silva; Susana Gea
Journal:  Front Immunol       Date:  2018-05-03       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.